← Browse by Condition
Medical Condition
refractory multiple myeloma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1
NCT05847569 Phase 2
Recruiting
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Enrollment
62 pts
Location
United States
Sponsor
Mayo Clinic
NCT06348108 Phase 1
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Alfred Chung, MD
NCT06138275 Phase 2
Recruiting
Elranatamab in R/R Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT05896228 Phase 2
Recruiting
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment
30 pts
Location
United States
Sponsor
Benjamin T Diamond, MD
NCT04162353 Phase 1
Recruiting
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Enrollment
12 pts
Location
China
Sponsor
iCell Gene Therapeutics